Study Title
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas (NCT01777152)
Trial Description
This is a double-blind, randomized, multicenter, phase III clinical trial to compare the efficacy and safety of brentuximab vedotin in combination with CHP with the standard-of-care CHOP in patients with CD30-positive mature T-cell lymphomas (MTCL) also known as peripheral T-cell lymphomas (PTCL).
Brentuximab vedotin is approved in select countries for the treatment of specific hematologic cancers after the failure of previous therapies, however its use in frontline mature T-cell lymphomas (MTCL) patients is strictly investigational.
This trial is sponsored by Millennium Pharmaceuticals/ Seattle Genetics. [1]
Study Data
- Condition:
- Anaplastic Large Cell Lymphoma (ALCL)
- T-Cell Lymphoma
- Non-Hodgkin Lymphoma (NHL)
- Interventions:
- Drugs used in this trial
- Brentuximab vedotin (Adcetris®; Seattle Genetics, Inc.)
- Doxorubicin (Doxil®; TTY Bio pharmacy Company Limited)
- Prednisolone (Orapred®; Concordia Healthcare Corp.)
- Vincristine (Oncovin® Genus Pharmaceuticals)
- Cyclophosphamide (Cytoxan® ;Bristol-Myers Squibb Company)
- Drugs used in this trial
- Phase: III
- Estimated Enrollment: 450
- Start: January 2013
- Estimated Completion: December 2019
- Last verified: June 2015
Study Schematic
Click here to Return to Drug map
Last Editorial review: July 15, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.
